MedinCell along with Teva gets approval for Uzedy (Risperidone), an extended-release injectable suspension treatment for adults with schizophrenia. This is the first approval for a product with MedinCell’s BEPO technology (also known as SteadyTeq); is based on encapsulation of drugs (active ingredients) in a biodegradable polymer matrix and releases drugs in a steady rate over extend period of time Read More..
Leave a Comment
You must be logged in to post a comment.